ClinicalTrials.gg
TerminatedNCT03560986Updated Aug 5, 2020Results posted

Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)

A Phase 3 interventional study of Neridronic acid 100 mg and Placebo in Complex Regional Pain Syndrome (CRPS), sponsored by Grünenthal GmbH. Terminated at 71 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-05.

Sponsored by Grünenthal GmbH · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Complex Regional Pain Syndromes with a site in United States — 20 open to participants now, 22 under way, 2 of them phase 3. Complex Regional Pain Syndromes · United States.

Enrollment
4th of 67
267 · median 30
Started
2018
with 9 others
Phase 3
12 of 88
2 open now
Registered
48th of 88
by date
Lead sponsor
3 of 88
Grünenthal GmbH

Among the 88 studies in Complex Regional Pain Syndromes with a site in United States, this one is the 4th largest by enrollment of the 67 interventional ones that give a count, is one of 10 that started in 2018, is one of 12 in phase 3, and was the 48th registered.

Complex Regional Pain Syndromes

206 studies on the registry are indexed under Complex Regional Pain Syndromes; 54 are open to participants now.

Browse Complex Regional Pain Syndromes studies →

Open to participants now

20 of the 88 studies in Complex Regional Pain Syndromes with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Complex Regional Pain Syndromes studies recruiting now, 17 (44%) set no upper age limit and 16 (41%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Complex Regional Pain Syndromes with a site in United States, or all of them as a file.
02

Study summary

The aim of this trial was to investigate the efficacy and safety of intravenous neridronic acid in subjects with Complex Regional Pain Syndrome (CRPS).

The trial consisted of an Enrollment Period lasting up to 60 days, Treatment Period A consisting of 4 infusions (neridronic acid 100 mg or placebo) over 10 days, and a Follow-up Period 1 until Week 26. At Week 26, participants meeting the pre-specified criteria entered the open-label Treatment Period B with 4 additional infusions (neridronic acid) over 10 days and follow-up visits until Week 52. Participants not meeting the pre-specified criteria to continue into Treatment Period B continued in Follow-up Period 2 until Week 52.

03

Conditions studied

  • Complex Regional Pain Syndrome (CRPS)

Keywords

  • Neridronic Acid
  • Neridronate
  • CRPS
  • Reflex sympathetic dystrophy (RSD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed.
  • Male or female participant at least 18 years of age at Visit 1.
  • A diagnosis of CRPS according to the clinical diagnostic criteria recommended by the International Association for the Study of Pain (IASP; "Budapest clinical criteria"), assessed at Visit 1. Signs and symptoms of CRPS must apply to an affected limb (arm or leg) and must demonstrate asymmetry with respect to the contralateral limb. The CRPS duration must be 2 years or less since onset of symptoms.
  • A baseline average pain intensity score of greater than or equal to 4 using an 11-point numerical rating scale (NRS), referring to the CRPS-affected limb (average of pain recorded over 7 days). The baseline average pain intensity score will be calculated automatically by the electronic diary, which must be checked prior to allocation at Visit 2. A participant who has not met average baseline pain intensity requirements (at least 4 average pain intensity ratings) due to lack of compliance with the electronic diary may be rescheduled for Visit 2 (1 time only), with appropriate re-training to ensure compliance with use of the electronic diary.
  • In stable treatment and follow-up therapy for CRPS for at least 1 month prior to allocation to treatment (Visit 2). Participants must have failed attempts with at least 2 available treatments for CRPS, 1 of which must have been a pharmacologic treatment.
  • Women of must have a negative urine Beta-human chorionic gonadotropin (ß-HCG) pregnancy test at Visit 1 and must be using 2 forms of medically acceptable , including at least 1 highly effective method of contraception with a low failure rate, defined as less than 1% per year, and a second medically acceptable method such as use of condoms with spermicide by their male partner. A barrier method alone is not acceptable. Highly effective methods of contraception must be used for at least 1 month prior to Visit 2 and for the duration of the trial. Male participants must use condom and spermicide during intercourse and must take care that the female sexual partner uses at least 1 additional method of contraception with a low failure rate defined as above, starting with Visit 2 until at least 4 weeks after the last medicinal product (IMP) infusion.
  • Participants must be able to communicate meaningfully, be able to differentiate with regard to location and intensity of the pain, and be able to answer the questions in the questionnaires used in this trial (assistance in filling out the questionnaires may be provided, if required due to motor or other physical impairment).

Exclusion criteria

Exclusion Criteria:

  • Evidence of renal impairment (estimated [eGFR] less than 30 mL/min/1.73 m2 using the 2009 Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] creatinine equation [Levey et al. 2009] or a urinary albumin to creatinine ratio [ACR] greater than 150 mg/g), based on central safety laboratory data obtained prior to Visit 2. Note: a single repeat laboratory test is allowed.
  • Serum calcium or magnesium outside of the central laboratory's reference range, based on central safety laboratory data obtained prior to Visit 2 (a single repeat laboratory test is allowed); a history of hypocalcemia or a metabolic disorder anticipated to increase risk for hypocalcemia (e.g., hypoparathyroidism); anticipated need for any new drug with known potential to cause hypocalcemia (e.g., aminoglycosides, new treatment with or dose adjustment of loop diuretics) during the trial. Participants on a stable dose of loop diuretics may receive treatment with IMP as long as no dosage increases in the diuretic medication are anticipated and calcium levels are in the reference range.
  • Vitamin D deficiency, defined as a 25(OH)D level less than 30 ng/mL (75 nmol/L), based on central safety laboratory data obtained prior to Visit 2 (up to 4 repeat laboratory tests are allowed). Participants with vitamin D deficiency should receive appropriate supplementation during the Enrollment Period. A vitamin D level of at least 30 ng/mL (75 nmol/L) must be documented prior to allocation to IMP.
  • interval (according to Fridericia's formula; QTcF) greater than 470 ms (average of 3 (ECGs) obtained at Visit 1) according to central ECG reading facility evaluation or QTcF greater than 470 ms at pre-dose ECG at Visit 2 according to the investigator's judgment; serum potassium outside the central laboratory's reference range at Visit 1(a single repeat laboratory test is allowed); clinically unstable cardiac disease, including: unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, active myocardial ischemia, or an indwelling pacemaker; evidence of complete left bundle branch block; complete atrioventricular block; history of Long QT Syndrome or a relative with this condition; or any history of or other known risk factor for torsade de pointes.
  • Participants receiving medications with a known risk of torsades de pointes within 7 days prior to allocation. Participants receiving selective serotonin re-uptake inhibitor antidepressants are eligible if the QT interval values do not meet the exclusion criteria, the medication was started at least 1 month prior to allocation, the dose is stable, and the dose is anticipated to remain stable throughout the trial.
  • Any prior use of a bisphosphonate for treatment of CRPS, any prior administration of a bisphosphonate within the previous year, anticipated requirement for treatment with a bisphosphonate for another condition such as osteoporosis during the trial, or administration of denosumab (Prolia®) or other bone turnover suppressing drugs within 6 months prior to Visit 1.
  • History of any allergic or reaction to neridronic acid or other bisphosphonate, acetaminophen, or to vitamin D or calcium supplements.
  • Recent tooth extraction or other invasive dental procedure (within 3 months prior to Visit 1), unhealed or infected extraction site, or significant dental/periodontal disease that may pre-dispose to need for tooth extraction or other invasive dental procedures during the trial. Participants with indeterminate, suspicious or unreliable dental history, in the opinion of the investigator, must undergo a dental examination prior to receiving treatment.
  • Evidence of denture-related gum trauma or improperly fitting dentures causing injury.
  • Prior radiation therapy of the head or neck (within 1 year of Visit 1).
  • History of within 2 years prior to Visit 1, with the exception of basal cell carcinoma.
  • Use of nerve blocks, ketamine infusions, intravenous immunoglobulin, acupuncture, electromagnetic field treatment, or initiation/implementation of radiofrequency ablation or other sympathectomy procedures, or peripheral nerve stimulation within 6 weeks prior to Visit 1.
  • Evidence of current alcohol or drug abuse, or history of alcohol or drug abuse within 2 years of Visit 1, based on participant history and physical examination and according to the investigator's judgment.
  • Any other severe medical condition, including severe depression, or any other severe mood disorder, that in the opinion of the investigator may affect efficacy or safety assessments or may compromise the participants safety during trial participation.
  • Women who are pregnant or breastfeeding.
  • Elevated or alanine aminotransferase greater than 2-fold , based on central safety laboratory data obtained at Visit 1, or current evidence of chronic liver disease. Safety laboratory testing may be repeated prior to Visit 2, and participants will be allowed in the trial if results of 2 consecutive tests, at least 3 days apart, are less than or equal to 2-fold upper limit of normal.
  • Participation in another drug trial within 3 months prior to Visit 1, or any previous trial involving neridronic acid, with the exception of participants participating in study KF7013-01 who were assigned to placebo and did not receive neridronic acid.
  • Participant is engaged in litigation related to their disability from CRPS in which monetary gain or loss (or other compensation) may affect their objective participation in the trial.
  • Participants taking forbidden concomitant medications/therapies or not being able to follow the rules of use of concomitant treatment.
  • Participants incapable of giving .

Criteria to continue into Treatment Period B

  • A value of at least 4 on the pain intensity question (question number 29, GLOBAL07) of the Patient-Reported Outcomes Measurement Information System (PROMIS®) (PROMIS-29 profile) at Visit 11.
  • The following exclusion criteria are not met:

    • Evidence of renal impairment (eGFR less than 30 mL/min/1.73 m2 using the 2009 CKD-EPI creatinine equation [Levey et al. 2009] or a urinary ACR greater than 150 mg/g), based on central safety laboratory data obtained prior to Visit 11. A single repeat laboratory test is allowed.
    • Corrected QT interval (QTcF) greater than 470 ms (average of 3 ECGs obtained at Visit 10) according to the central ECG reading facility evaluation or QTcF greater than 470 ms at pre-dose ECG at Visit 11 according to the investigator's judgment; serum potassium outside the central laboratory's reference range at Visit 10 (a single repeat laboratory test is allowed); clinically unstable cardiac disease, including: unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, active myocardial ischemia, or an indwelling pacemaker; evidence of complete left bundle branch block; complete atrioventricular block; any other known risk factor for torsade de pointes.
    • Participants receiving medications with a known risk of torsades de pointes within 7 days prior to re-allocation.
    • Participants taking forbidden concomitant medications/therapies or not being able to follow the rules of use of concomitant treatment.
    • Recent tooth extraction or other invasive dental procedure (within 3 months prior to Visit 11), unhealed or infected extraction site, or significant dental/periodontal disease that may pre-dispose to need for tooth extraction or other invasive dental procedures during the further course of the trial.
    • Serum calcium outside of the central laboratory's reference range, despite appropriate supplementation between Visit 10 and Visit 11, based on the last central safety laboratory data obtained prior to Visit 11. Two repeat laboratory tests are allowed.
    • Vitamin D deficiency prior to IMP re-allocation, defined as a 25(OH)D level less than 30 ng/mL (75 nmol/L), based on the last central safety laboratory data obtained prior to Visit 11, i.e., inability to normalize 25(OH)D levels to at least 30 ng/mL (75 nmol/L) despite appropriate supplementation between Visit 10 and Visit 11. Two repeat laboratory tests are allowed.
    • Elevated aspartate aminotransferase or alanine aminotransferase greater than 2-fold upper limit of normal, based on central safety laboratory data obtained at Visit 10, or current evidence of chronic liver disease. A single repeat laboratory test is allowed.
  • No other criterion for trial and/or IMP discontinuation is met.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
267 participants (actual)

Study arms

  • Experimental
    Neridronic acid

    Neridronic acid 100 mg - 4 intravenous (i.v.) infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The investigational medicinal product (IMP) was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration. The maximum neridronic acid dose was 800 mg: 400 mg in Treatment Period A and 400 mg in Treatment Period B.

    Drug: Neridronic acid 100 mg

  • Placebo comparator
    Placebo

    Matching placebo - 4 intravenous infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The IMP was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.

    Drug: Placebo

Interventions

  • 100 mg neridronic acid supplied in glass vials in 8 mL of excipients.

  • DrugPlacebo

    Glass vials with matching placebo.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in the Average Pain Intensity Score (Weekly Average of Pain Values Recorded Daily in the Electronic Diary)

    In the Baseline Phase and in Treatment Period A/Follow-up Period 1, participants were asked to assessed their average CRPS-related pain on an 11-point numerical rating scale (NRS) - from 0 = "no pain" to 10 = "pain as bad as you can imagine" and report it once daily (in the evening, 24-hour recall) in an electronic diary. Changes from baseline (average for the Baseline Phase) to the weekly average for Week 12 were calculated.

    Time frame: From the Baseline Phase (Day -7 to Day -1) to Week 12

Secondary outcomes

  1. Change From Baseline to Week 26 in the Average Pain Intensity Recorded on the Tablet Computer

    11-point NRS - from 0 = "no pain" to 10 = "pain as bad as you can imagine" - reported at the visits on a tablet computer (24-hour recall). Changes from baseline to Week 26 were planned to be analyzed.

    Time frame: From baseline (Visit 2 [Day 1]) to Visit 11 (Week 26)

  2. Pain Response to Treatment, Defined as at Least 30% Decrease From Baseline in the Average Pain Intensity at Week 12, Recorded on the Tablet Computer

    11-point NRS - from 0 = "no pain" to 10 = "pain as bad as you can imagine" - reported at the visits on a tablet computer (24-hour recall). The number of participants with response at Week 12 was planned to be determined.

    Time frame: From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)

  3. Pain Response to Treatment, Defined as at Least 30% Decrease From Baseline in the Average Pain Intensity at Week 26, Recorded on the Tablet Computer

    11-point NRS - from 0 = "no pain" to 10 = "pain as bad as you can imagine" - reported at the visits on a tablet computer (24-hour recall). The number of participants with response at Week 26 was planned to be determined.

    Time frame: From baseline (Visit 2 [Day 1]) to Visit 11 (Week 26)

  4. Change From Baseline to Week 12 in the Pain Intensity Level of Dynamic Mechanical Allodynia (DMA)

    Dynamic mechanical allodynia: a tactile stimulus is applied in a single sweeping motion (1 cm to 2 cm length) on the skin on the affected limb. The participants are asked to judge the stimulus intensity by means of an NRS (0 to 10). "0" in this case means "no pain". Each "pricking", "stinging" or "burning" sensation is defined as a painful sensation, which should always be evaluated by giving a value greater than "0". "10" corresponds to the individual maximum pain imaginable. Change from baseline was planned to analyzed.

    Time frame: From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)

  5. Change From Baseline to Week 12 in the Pressure Pain Threshold (PPT) Ratio for the Thenar Muscle/Abductor Hallucis Muscle

    Pressure pain threshold: using a pressure algometer (contact area 1 cm2), the threshold for pressure-induced pain is measured on the thenar muscle/abductor hallucis muscle in 3 series of slowly increasing stimulus intensities (at a rate of about 50 kPa/s). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The ratio of the thresholds of the affected limb versus the unaffected limb was planned to be calculated.

    Time frame: From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)

  6. Change From Baseline to Week 12 in the Ratio of the Figure of Eight Measurements of the Affected Limb Versus the Unaffected Limb

    In participants with the CRPS sign of edema on the CRPS severity score at baseline, circumference of the hand or foot will be measured by the investigator with measurement tape using the figure-of-eight method at both the affected limb and the contralateral unaffected limb. Each measurement will be performed 3 times. The average of the 3 measurements will be used for further analysis. The ratio of the averages of the affected limb versus the unaffected limb was planned to be calculated and used for the determination of the change from baseline.

    Time frame: From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)

07

Results

Posted Aug 5, 2020
Limitations and caveats
A pre-specified interim analysis was conducted on pooled primary endpoint data of studies KF7013-04 and KF7013-02 (NCT03530345). The interim analysis indicated futility (neridronate unlikely to be superior to placebo) and both studies were stopped.

Participant flow

First participant enrollment on 31 May 2018. After a pooled interim analysis of primary endpoint data of studies KF7013-04 and KF7013-02 (NCT03530345), recruitment was stopped as interim results indicated futility. Last participant's last assessment was on 01 Aug 2019.

Treatment Period A/Follow-up Period 1
Participant flow — Treatment Period A/Follow-up Period 1
MilestoneNeridronic Acid - Treatment Period APlacebo - Treatment Period A
Started4851
Treatment period a completers4545
Completed1213
Not completed3638
Withdrew: Withdrawal by subject31
Withdrew: Lost to follow-up11
Withdrew: Protocol violation01
Withdrew: Disc. before end of follow-up period 13235
Treatment Period B/Follow-up Period 2
Participant flow — Treatment Period B/Follow-up Period 2
MilestoneNeridronic Acid - Treatment Period APlacebo - Treatment Period A
Started98
Treatment period b completers88
Completed10
Not completed88
Withdrew: Adverse event10
Withdrew: Withdrawal by subject01
Withdrew: Disc. before end of follow-up period 277

Outcome measures

PrimaryChange From Baseline to Week 12 in the Average Pain Intensity Score (Weekly Average of Pain Values Recorded Daily in the Electronic Diary)

In the Baseline Phase and in Treatment Period A/Follow-up Period 1, participants were asked to assessed their average CRPS-related pain on an 11-point numerical rating scale (NRS) - from 0 = "no pain" to 10 = "pain as bad as you can imagine" and report it once daily (in the evening, 24-hour recall) in an electronic diary. Changes from baseline (average for the Baseline Phase) to the weekly average for Week 12 were calculated.

Time frame:
From the Baseline Phase (Day -7 to Day -1) to Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 12 in the Average Pain Intensity Score (Weekly Average of Pain Values Recorded Daily in the Electronic Diary)
units on a scaleNeridronic Acid - Treatment Period APlacebo - Treatment Period A
Change From Baseline to Week 12 in the Average Pain Intensity Score (Weekly Average of Pain Values Recorded Daily in the Electronic Diary)-1.28 ± 0.270-1.71 ± 0.268
Statistical analysis
  • Neridronic Acid - Treatment Period A vs Placebo - Treatment Period A · Mixed Models Analysis · p = 0.2522 (2-sided p-value for testing superiority of neridronic acid 400 mg compared to placebo.) · Mean difference (net): 0.43 · 95% CI -0.31 to 1.17The primary endpoint estimate was the least squares mean differences of change from baseline in pain NRS (electronic diary) at Week 12 between neridronate and Placebo.
SecondaryChange From Baseline to Week 26 in the Average Pain Intensity Recorded on the Tablet Computer

11-point NRS - from 0 = "no pain" to 10 = "pain as bad as you can imagine" - reported at the visits on a tablet computer (24-hour recall). Changes from baseline to Week 26 were planned to be analyzed.

Time frame:
From baseline (Visit 2 [Day 1]) to Visit 11 (Week 26)

No measurements were reported for this outcome.

SecondaryPain Response to Treatment, Defined as at Least 30% Decrease From Baseline in the Average Pain Intensity at Week 12, Recorded on the Tablet Computer

11-point NRS - from 0 = "no pain" to 10 = "pain as bad as you can imagine" - reported at the visits on a tablet computer (24-hour recall). The number of participants with response at Week 12 was planned to be determined.

Time frame:
From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)

No measurements were reported for this outcome.

SecondaryPain Response to Treatment, Defined as at Least 30% Decrease From Baseline in the Average Pain Intensity at Week 26, Recorded on the Tablet Computer

11-point NRS - from 0 = "no pain" to 10 = "pain as bad as you can imagine" - reported at the visits on a tablet computer (24-hour recall). The number of participants with response at Week 26 was planned to be determined.

Time frame:
From baseline (Visit 2 [Day 1]) to Visit 11 (Week 26)

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 12 in the Pain Intensity Level of Dynamic Mechanical Allodynia (DMA)

Dynamic mechanical allodynia: a tactile stimulus is applied in a single sweeping motion (1 cm to 2 cm length) on the skin on the affected limb. The participants are asked to judge the stimulus intensity by means of an NRS (0 to 10). "0" in this case means "no pain". Each "pricking", "stinging" or "burning" sensation is defined as a painful sensation, which should always be evaluated by giving a value greater than "0". "10" corresponds to the individual maximum pain imaginable. Change from baseline was planned to analyzed.

Time frame:
From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 12 in the Pressure Pain Threshold (PPT) Ratio for the Thenar Muscle/Abductor Hallucis Muscle

Pressure pain threshold: using a pressure algometer (contact area 1 cm2), the threshold for pressure-induced pain is measured on the thenar muscle/abductor hallucis muscle in 3 series of slowly increasing stimulus intensities (at a rate of about 50 kPa/s). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The ratio of the thresholds of the affected limb versus the unaffected limb was planned to be calculated.

Time frame:
From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 12 in the Ratio of the Figure of Eight Measurements of the Affected Limb Versus the Unaffected Limb

In participants with the CRPS sign of edema on the CRPS severity score at baseline, circumference of the hand or foot will be measured by the investigator with measurement tape using the figure-of-eight method at both the affected limb and the contralateral unaffected limb. Each measurement will be performed 3 times. The average of the 3 measurements will be used for further analysis. The ratio of the averages of the affected limb versus the unaffected limb was planned to be calculated and used for the determination of the change from baseline.

Time frame:
From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events were documented from the time of enrollment (i.e., the time the informed consent form was signed) up to the time of the last protocol scheduled contact, i.e., date of last visit/contact (could be a phone call, e.g., in case of withdrawal). Only treatment emergent adverse events (TEAEs, i.e., those reported from baseline (after first administration of study medication) are reported in the tables below.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baseline to Week 26: Placebo TPA0/51 (0%)3/51 (5.9%)40/51 (78.4%)
Baseline to Week 26: Neridronic Acid TPA0/48 (0%)2/48 (4.2%)40/48 (83.3%)
Week 26 to Week 52: Placebo TPA0/43 (0%)0/43 (0%)1/43 (2.3%)
Week 26 to Week 52: Placebo TPA, Neridronic Acid TPB0/8 (0%)1/8 (12.5%)6/8 (75%)
Week 26 to Week 52: Neridronic Acid TPA0/39 (0%)0/39 (0%)0/39 (0%)
Week 26 to Week 52: Neridronic Acid TPA, Neridronic Acid TPB0/9 (0%)1/9 (11.1%)5/9 (55.6%)
Most frequent serious events
Most frequent serious events
EventBaseline to Week 26: Placebo TPABaseline to Week 26: Neridronic Acid TPAWeek 26 to Week 52: Placebo TPAWeek 26 to Week 52: Placebo TPA, Neridronic Acid TPBWeek 26 to Week 52: Neridronic Acid TPAWeek 26 to Week 52: Neridronic Acid TPA, Neridronic Acid TPB
FallInjury, poisoning and procedural complications0/510/480/431/80/390/9
Urinary tract infectionInfections and infestations0/511/480/430/80/391/9
NephrolithiasisRenal and urinary disorders0/511/480/430/80/390/9
Silent myocardial infarctionCardiac disorders0/511/480/430/80/390/9
Decreased appetiteMetabolism and nutrition disorders1/510/480/430/80/390/9
DysaesthesiaNervous system disorders1/510/480/430/80/390/9
OverdoseInjury, poisoning and procedural complications1/510/480/430/80/390/9
Retinal detachmentEye disorders1/510/480/430/80/390/9
Most frequent other events
Showing 10 of 49
Most frequent other events
EventBaseline to Week 26: Placebo TPABaseline to Week 26: Neridronic Acid TPAWeek 26 to Week 52: Placebo TPAWeek 26 to Week 52: Placebo TPA, Neridronic Acid TPBWeek 26 to Week 52: Neridronic Acid TPAWeek 26 to Week 52: Neridronic Acid TPA, Neridronic Acid TPB
NauseaGastrointestinal disorders8/512/480/432/80/391/9
Acute phase reactionGeneral disorders5/518/480/432/80/390/9
DiarrhoeaGastrointestinal disorders2/512/480/431/80/390/9
VomitingGastrointestinal disorders2/510/480/431/80/390/9
HyperglycaemiaMetabolism and nutrition disorders2/511/480/431/80/390/9
ArthralgiaMusculoskeletal and connective tissue disorders3/513/480/431/80/391/9
PruritusSkin and subcutaneous tissue disorders0/510/480/431/80/391/9
HypersensitivityImmune system disorders0/510/480/431/80/390/9
AnaemiaBlood and lymphatic system disorders0/510/480/431/80/390/9
Clostridium difficile infectionInfections and infestations0/510/480/431/80/390/9

Baseline characteristics

Safety Set; all participants treated in Treatment Period A.

Age, Continuous
Age, Continuous(years)Neridronic Acid - Treatment Period APlacebo - Treatment Period ATotal
Mean49.5 ± 12.750.4 ± 12.650.0 ± 12.6
Age, Customized
Age, Customized(Participants)Neridronic Acid - Treatment Period APlacebo - Treatment Period ATotal
<18 years000
From 18 to <65 years424688
From 65 to <85 years6511
85 years and above000
Sex: Female, Male
Sex: Female, Male(Participants)Neridronic Acid - Treatment Period APlacebo - Treatment Period ATotal
Female353671
Male131528
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Neridronic Acid - Treatment Period APlacebo - Treatment Period ATotal
American Indian or Alaska Native213
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American369
White424486
More than one race101
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Neridronic Acid - Treatment Period APlacebo - Treatment Period ATotal
Canada145
United States373673
Czechia549
United Kingdom257
Slovakia325
CRPS type
CRPS type(Participants)Neridronic Acid - Treatment Period APlacebo - Treatment Period ATotal
CRPS Type I383371
CRPS Type II5914
Unknown CRPS Type5914
Time since onset of CRPS symptoms
Time since onset of CRPS symptoms(months)Neridronic Acid - Treatment Period APlacebo - Treatment Period ATotal
Median12.88 (7.30 to 18.90)11.80 (6.00 to 18.57)12.33 (6.63 to 18.57)
Time since diagnosis of CRPS
Time since diagnosis of CRPS(months)Neridronic Acid - Treatment Period APlacebo - Treatment Period ATotal
Median5.92 (0.87 to 11.03)5.83 (0.03 to 15.03)5.83 (0.47 to 12.63)
08

Study locations

71 sites
  • US446 - Clinical Trial Connection
    Cottonwood, Arizona 86326, United States
  • US453 - Physicians Research Group II, LLC
    Tempe, Arizona 85284, United States
  • US428 - Quality of Life Medical and Research Center LLC
    Tucson, Arizona 85712, United States
  • US422 - Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • US454 - Alliance Research Institute
    Canoga Park, California 91304, United States
  • US415 - Clearview Medical Research LLC
    Canyon Country, California 91351, United States
  • US410 - Alliance Research Centers
    Laguna Hills, California 92653, United States
  • US432 - Torrance Clinical Research Institute Inc.
    Lomita, California 90717, United States
  • Us414 - Alexander Ford Md
    Los Angeles, California 90035, United States
  • US441 - Samaritan Center for Medical Research
    Los Gatos, California 95032, United States
  • US406 - CI Trials
    Santa Ana, California 92705, United States
  • US411 - Syrentis Clinical Research
    Santa Ana, California 92705, United States
  • US420 - Mountain View Clinical Research, INC
    Denver, Colorado 80209, United States
  • US447 - ASCLEPES Research Centers
    Brooksville, Florida 34613, United States
  • US457 - Florida Spine Institute
    Clearwater, Florida 33765, United States
  • US430 - South Lake Pain Institute
    Clermont, Florida 34711, United States
  • US434 - Finlay Medical Research
    Miami, Florida 33126, United States
  • US407 - Oceane 7 Medical and Research Center, Inc.
    Miami, Florida 33144, United States
  • US436 - Cordova Research Institute
    Miami, Florida 33155, United States
  • US417 - Tampa Pain Relief Center
    Tampa, Florida 33603, United States
  • US403 - Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • US404 - Infinite Clinical Trials
    Riverdale, Georgia 30274, United States
  • US424 - Georgia Neurology and Sleep Medicine Assoc.
    Suwanee, Georgia 30024, United States
  • US431 - Injury Care Research, LLC
    Boise, Idaho 83713, United States
  • US437 - Great Lakes Clinical Trials LLC
    Chicago, Illinois 60640, United States
  • US435 - Centex Studies Inc
    Lake Charles, Louisiana 70601, United States
  • US448 - The Center for Rheumatology and Bone Research
    Wheaton, Maryland 20902, United States
  • US450 - SRI International
    Plymouth, Michigan 48170, United States
  • US449 - Michigan Pain Consultants
    Wyoming, Michigan 49503, United States
  • US433 - Creighton University - Osteoporosis Research Center
    Omaha, Nebraska 68122, United States
  • US419 - Manhattan Behavioral Medicine
    New York, New York 10036, United States
  • US440 - OnSite Clinical Solutions LLC
    Charlotte, North Carolina 28210, United States
  • US405 - OnSite Clinical Solutions LLC
    Hickory, North Carolina 28601, United States
  • US416 - Medical Research International
    Oklahoma City, Oklahoma 73109, United States
  • US429 - Lehigh Valley Health
    Allentown, Pennsylvania 18103, United States
  • US438 - Abington Neurological Associates, LTD.
    Willow Grove, Pennsylvania 19090, United States
  • US425 - PCPMG Clinical Research Unit LLC
    Greenville, South Carolina 29601, United States
  • US423 - Biopharma Informatic Inc. Research Center
    Houston, Texas 77043, United States
  • US443 - Centex Studies Inc
    Houston, Texas 77058, United States
  • US421 - Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • US445 - Exemplar Research Inc
    Morgantown, West Virginia 26505, United States
  • CA404 - Jeffrey Weinberg Medicine Professional Corporation c/o Jacobs Pain Center
    Markham, Ontario L3R 9W9, Canada
  • CA406 - Malton Medical Centre (attn: Vrijender Singh)
    Mississauga, Ontario L4V 1P1, Canada
  • CA402 - SKDS Research Inc
    Newmarket, Ontario L3Y 5G8, Canada
  • CA407 - King Street Medical Clinic
    Oshawa, Ontario L1H 1G6, Canada
  • CA403 - Bluewater Clinical Research Group
    Sarnia, Ontario N7T 4X3, Canada
  • CA405 - Canadian Centre for Clinical TrialsCCCT
    Thornhill, Ontario L4J 1W3, Canada
  • CZ403 - CCBR Ostrava
    Ostrava, 70 200, Czechia
  • CZ402 - CCR Czech a,s.
    Pardubice, 53 002, Czechia
  • CZ401 - FORBELI s.r.o.
    Prague 6, 16 000, Czechia
  • PL405 - Medical Solutions
    Elblag, 82-300, Poland
  • PL404 - Zagiel Med Sp Zoo
    Lublin, 20-362, Poland
  • PL403 - Alergo-Med Specjalistyczna Przychodnia Lekarska Sp.z o.o
    Tarnów, 33-100, Poland
  • RS401 - Clinical Center of Serbia, Clinic for physical medicine and rehabilitation
    Belgrade, 11000, Serbia
  • RS403 - Clinical Center Kragujevac, Department of Physical Medicine and rehabilitation
    Kragujevac, 34000, Serbia
  • RS404 - Clinical Center Nis, Clinic for Physical Medicine and Rehabilitation
    Nis, 18000, Serbia
  • RS405 - Clinical Center of Vojvodina, Medical Rehabilitation Clinic
    Novi Sad, 21000, Serbia
  • SK402 - MUDr. Beata Dupejova, neurologicka ambulancia sro
    Banska Bystrica, 97404, Slovakia
  • SK404 - Medical Center Konzilium
    Dubnica nad Vahom, 018 41, Slovakia
  • SK403 - NEURES, s.r.o.
    Krompachy, 5342, Slovakia
  • SK401 - MUDr. Viliam Cíbik, PhD, Algeziologická ambulancia
    Pruske, 1852, Slovakia
  • GB413 - MAC Clinical Research
    Barnsley, S75 3DL, United Kingdom
  • GB412 - MAC Clinical Research
    Blackpool, FY2 0JH, United Kingdom
  • GB415 - MAC Clinical Research
    Cannock, WS11 0BN, United Kingdom
  • GB416 - Royal Devon and Exeter Hospital
    Exeter, EX2 5DW, United Kingdom
  • GB410 - MAC Clinical Research
    Leeds, LS10 1DU, United Kingdom
  • GB409 - MAC Clinical Research
    Liverpool, L34 1BH, United Kingdom
  • GB407 - Pain and Neuromodulation Centre Ground Floor, Gassiot House, St Thomas Hospital
    London, SE1 7EH, United Kingdom
  • GB402 - St Pancras Clinical Research
    London, WC1X 8QD, United Kingdom
  • GB408 - MAC Clinical Research
    Manchester, M13 9NQ, United Kingdom
  • GB414 - MAC Clinical Research
    Stockton-on-Tees, TS17 6EW, United Kingdom
09

References and documents

Publications

  • Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006. Erratum In: Ann Intern Med. 2011 Sep 20;155(6):408. PubMed 19414839 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Information available on the Grünenthal Group Web Site (see URL below for details); according to the European Federation of Pharmaceutical Industries and Associations (EFPIA) Data Sharing Principles.

Supporting information: Study protocol, Statistical analysis plan

Data sharing details ↗ · www.grunenthal.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Aug 2019, 14 months.

Results were first posted in Aug 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2018
First posted
Jun 19, 2018
StartActual
May 31, 2018
Primary completionActual
Aug 1, 2019
CompletionActual
Aug 1, 2019
Results first posted
Aug 5, 2020
Last update
Aug 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03560986
Lead sponsor
Grünenthal GmbH
Responsible party
Sponsor
First posted
Jun 19, 2018
Start date
May 31, 2018
Primary completion
Aug 1, 2019
Completion
Aug 1, 2019
Results posted
Aug 5, 2020
Last update
Aug 5, 2020

Study contacts

Grünenthal Study Director
study director · Grünenthal GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Neridronic acid

Start the discussion